10:22 AM EDT, 04/21/2026 (MT Newswires) -- Allogene Therapeutics ( ALLO ) said Tuesday it has received clearance from regulators in South Korea and Australia to expand its pivotal phase 2 study evaluating cemacabtagene ansegedleucel in first-line consolidation treatment for patients with large B-cell lymphoma into those two countries.

With the clearances, the study is set to expand to more than 80 global sites from more than 60 sites currently in North America, the company said.

The study is expected to enroll about 220 patients by the end of 2027, with an interim analysis of event-free survival anticipated in mid-2027 and the primary analysis in mid-2028, according to a statement.

Positive results from the study could support a biologics license application submission, Allogene said.

Price: 2.31, Change: -0.12, Percent Change: -4.75